Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA... Read more.
V.F. Corporation 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuits Against V.F. Corporation – VFC
NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles... Read more.
Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025
Highlights from the Data Presentation VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related... Read more.
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Enlicitide has the potential to be the first approved oral PCSK9 inhibitor designed to deliver antibody-like efficacy and help address critical unmet needs for patients... Read more.
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety... Read more.
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
NEW ORLEANS–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve... Read more.
Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Life Insurance Segment
SINGAPORE–(BUSINESS WIRE)–#insurance—AM Best is maintaining its stable outlook on the New Zealand life insurance segment, based in part on improving... Read more.
Stepful Keeps Healthcare Training Free for Military Families Amid Government Shutdown
NEW YORK–(BUSINESS WIRE)–As the government shutdown continues to disrupt funding for education and workforce programs, Stepful, recently named the #1... Read more.
Anumana Advances AI-Driven Cardiovascular Science with Late-Breaking Heart Failure Study and Multiple Abstracts at AHA 2025
Simultaneous publication in Journal of the American College of Cardiology demonstrates impact of ECG-AI on heart failure risk assessment CAMBRIDGE, Mass.–(BUSINESS... Read more.
Teledyne FLIR Defense Names Riyadh-Based Managing Director for Middle East and North Africa
Tarik Solomon to lead regional growth strategy, strengthen partnerships, and help Teledyne position the Kingdom as a hub for next-generation defense and dual-use... Read more.